BSE Live
Mar 13, 16:01Prev. Close
1825.00
Open Price
1797.60
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 13, 15:59Prev. Close
1825.30
Open Price
1822.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1801.60 (797)
| Key Financial Ratios of Sun Pharmaceutical Industries (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | -6.10 | -13.70 | 5.00 | 16.40 | 13.40 | |
| Diluted EPS (Rs.) | -6.10 | -13.70 | 5.00 | 16.40 | 13.40 | |
| Cash EPS (Rs.) | -3.93 | -13.16 | 5.82 | 17.12 | 13.98 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 109.78 | 35.77 | 75.21 | 76.07 | 64.51 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 109.78 | 35.77 | 75.21 | 76.07 | 64.51 | |
| Dividend / Share(Rs.) | 3.00 | 1.50 | 5.00 | 4.25 | 3.50 | |
| Revenue from Operations/Share (Rs.) | 38.71 | 13.66 | 23.49 | 38.78 | 30.01 | |
| PBDIT/Share (Rs.) | -1.68 | 0.94 | 7.24 | 20.30 | 14.67 | |
| PBIT/Share (Rs.) | -4.87 | 0.45 | 6.41 | 19.57 | 14.05 | |
| PBT/Share (Rs.) | -7.53 | -13.52 | 6.40 | 16.67 | 14.04 | |
| Net Profit/Share (Rs.) | -7.12 | -13.66 | 4.99 | 16.39 | 13.36 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | -4.32 | 6.88 | 30.80 | 52.34 | 48.87 | |
| PBIT Margin (%) | -12.56 | 3.28 | 27.27 | 50.45 | 46.80 | |
| PBT Margin (%) | -19.44 | -99.02 | 27.26 | 42.97 | 46.78 | |
| Net Profit Margin (%) | -18.38 | -99.99 | 21.23 | 42.27 | 44.52 | |
| Return on Networth / Equity (%) | -6.48 | -38.18 | 6.63 | 21.54 | 20.71 | |
| Return on Capital Employed (%) | -3.81 | 0.91 | 8.19 | 24.97 | 21.32 | |
| Return on Assets (%) | -3.93 | -20.44 | 5.58 | 18.58 | 18.19 | |
| Total Debt/Equity (X) | 0.24 | 0.33 | 0.01 | 0.01 | 0.01 | |
| Asset Turnover Ratio (%) | 0.31 | 0.25 | 0.26 | 0.48 | 0.44 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 0.49 | 1.40 | 3.37 | 3.90 | 5.97 | |
| Quick Ratio (X) | 0.30 | 1.15 | 2.61 | 3.27 | 5.18 | |
| Inventory Turnover Ratio (X) | 1.46 | 1.00 | 0.94 | 1.51 | 1.21 | |
| Dividend Payout Ratio (NP) (%) | -48.97 | -10.98 | 100.24 | 25.92 | 26.19 | |
| Dividend Payout Ratio (CP) (%) | -88.75 | -11.39 | 85.95 | 24.82 | 25.03 | |
| Earnings Retention Ratio (%) | 148.97 | 110.98 | -0.24 | 74.08 | 73.81 | |
| Cash Earnings Retention Ratio (%) | 188.75 | 111.39 | 14.05 | 75.18 | 74.97 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 216,735.09 | 121,019.78 | 84,360.34 | 57,690.01 | 44,552.43 | |
| EV/Net Operating Revenue (X) | 27.03 | 42.78 | 34.69 | 14.37 | 14.34 | |
| EV/EBITDA (X) | -624.52 | 621.16 | 112.59 | 27.45 | 29.33 | |
| MarketCap/Net Operating Revenue (X) | 26.41 | 41.98 | 34.85 | 14.69 | 14.72 | |
| Retention Ratios (%) | 148.97 | 110.98 | -0.24 | 74.07 | 73.80 | |
| Price/BV (X) | 9.31 | 16.03 | 10.88 | 7.49 | 6.85 | |
| Price/Net Operating Revenue | 26.41 | 41.98 | 34.85 | 14.69 | 14.72 | |
| Earnings Yield | -0.01 | -0.02 | 0.01 | 0.03 | 0.03 |
09.03.2026
09.03.2026
04.02.2026
Buy Sun Pharmaceutical Industries; target of Rs 1900: Prabhudas Lilladher
03.02.2026
Sun Pharma Consolidated December 2025 Net Sales at Rs 15,520.54 crore, up 13.49% Y-o-Y
03.02.2026
Sun Pharma Consolidated December 2025 Net Sales at Rs 15,520.54 crore, up 13.49% Y-o-Y
03.02.2026
Sun Pharma Standalone December 2025 Net Sales at Rs 5,687.77 crore, down 8.14% Y-o-Y
11.11.2025
Sun Pharma Standalone September 2025 Net Sales at Rs 4,548.11 crore, down 11.3% Y-o-Y
01.08.2025
Sun Pharma Consolidated June 2025 Net Sales at Rs 13,851.40 crore, up 9.47% Y-o-Y
13.03.2026
13.03.2026
11.03.2026
Granules India looks for M&A as it expands beyond the US, deepens focus on complex generics
11.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth